These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35231990)

  • 1. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
    Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
    [No Abstract]   [Full Text] [Related]  

  • 2. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
    Bellofiore C; Benvenuti P; Mina R; Basset M; Foli A; Nanci M; Nuvolone M; Guida G; Attanasio A; Mussinelli R; Mangiacavalli S; Cartia CS; Masoni V; Palumbo M; Cani L; Oliva S; Consoli U; Conticello C; Di Raimondo F; Arcaini L; Bringhen S; Merlini G; Palladini G; Milani P
    Hematol Oncol; 2024 Jul; 42(4):e3289. PubMed ID: 38824453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
    Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
    Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
    Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
    ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
    Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
    Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
    Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
    Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
    Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Daratumumab for the treatment of primary systemic amyloidosis: a multicenter retrospective analysis].
    Liu Y; Huang XH; Duan WB; Fang BJ; Huang DP; Zhang YH; Xu L; Zhang HY; Zhang H; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):987-992. PubMed ID: 34689520
    [No Abstract]   [Full Text] [Related]  

  • 11. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
    Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
    Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
    Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
    Lecumberri R; Krsnik I; Askari E; Sirvent M; González-Pérez MS; Escalante F; Pradillo V; Tamariz LE; Cánovas V; Alegre A; Gironella M; González-García ME; Infante MS; Lakhwani S; Martínez-Bilbao C; Dourdil V; Ramírez-Payer Á; Sarrá J; Cibeira MT
    Amyloid; 2020 Sep; 27(3):163-167. PubMed ID: 32106714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
    Milani P; Fazio F; Basset M; Berno T; Larocca A; Foli A; Riva M; Benigna F; Oliva S; Nuvolone M; Rodigari L; Petrucci MT; Merlini G; Palladini G
    Am J Hematol; 2020 Aug; 95(8):900-905. PubMed ID: 32282971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
    Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
    Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
    Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab.
    Szalat RE; Gustine J; Sloan JM; Edwards CV; Sanchorawala V
    Am J Hematol; 2022 Jan; 97(1):79-89. PubMed ID: 34739735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.
    Shen KN; Gao YJ; Chang L; Zhang L; Cao XX; Tian Z; Wang YN; Zhou DB; Li J
    Haematologica; 2024 Jul; 109(7):2355-2358. PubMed ID: 38546676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.